在抗血素缺乏的孕妇和同卵性HBS II突变后LMWH给药后,血素生成减少
Ivana Malikova1, Martina Husakova1, Jana Bilkova2
1Central Hematological Laboratory, General University Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic.
概括
怀孕妇女的抗血缺乏症具有较高的血栓性风险. 血栓生成试验有效监测低分子量肝素预防,防止同卵性病例的并发症.
科学领域:
- 产科和妇科 产科和妇科
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗血素 (AT) 缺乏症,特别是在具有同卵性HBS II突变的孕妇中,由于增加了血素生成 (TG) 而导致罕见但显著的血栓性风险.
- 在怀孕期间对这些患者的预防性治疗具有挑战性.
- 严重的AT缺乏症可能会限制标准抗Xa因子 (抗FXa) 测试的效用,以监测低分子量肝素 (LMWH) 疗效.
研究的目的:
- 评估血栓生成试验 (TGA) 和抗FXa试验在监测同卵性AT缺乏症的孕妇预防性LMWH治疗中的有效性.
- 将TGA发现与接受LMWH的孕妇和非孕妇的TGA发现进行比较.
- 评估TGA在治疗严重AT缺乏症中进行血栓预防的临床效用.
主要方法:
- 一个28岁女性同卵性AT缺乏症 (SERPINC1基因突变c.391C>T) 在怀孕期间接受LMWH预防的案例研究.
- 使用血栓生成试验 (TGA) 和抗Xa因子 (抗FXa) 测试进行监测.
- 将TGA结果与接受LMWH治疗的孕妇和非孕妇对照组的数据进行比较.
主要成果:
- 血生成试验 (TGA) 在所有监测组中显示TG显著下降 (P < .05),表明有效的LMWH预防.
- 这位患有同卵性AT缺乏症的妇女在整个怀孕期间没有出现血栓并发症.
- TGA对于监测LMWH疗效非常有价值,特别是当由于严重的AT缺乏症而导致抗FXa水平较低时.
结论:
- 在怀孕期间与LMWH治疗一起对血栓生成 (TG) 的持续监测对于治疗抗血栓缺乏症患者至关重要.
- 结合TG监测,LMWH和抗血素 (分娩前和分娩后) 的综合方法可以提高患者的治疗结果和护理质量.
- 在复杂的血栓预防方案中,TGA提供了一种可靠的方法来评估抗凝剂的疗效.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
749
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
749
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:24Disorders of Hemostasis
989
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
989
01:30Venous Thrombosis I: Introduction
12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12